BRPI0808421A2 - Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula. - Google Patents

Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula.

Info

Publication number: BRPI0808421A2
Authority: BR; Brazil
Prior art keywords: cell; inducing; cytotoxic; exosome; vaccine
Prior art date: 2007-02-21

Application number

Other languages

English (en)

Inventor

Ryuji Ohsawa

Takuya Tsunoda

Original Assignee

Oncotherapy Science Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2007-02-21

Filing date

2008-02-21

Publication date

2017-08-29

2008-02-21 Application filed by Oncotherapy Science Inc filed Critical Oncotherapy Science Inc

2008-02-21 Priority to BR122020021065-6A priority Critical patent/BR122020021065B1/pt

2017-08-29 Publication of BRPI0808421A2 publication Critical patent/BRPI0808421A2/pt

2021-10-05 Publication of BRPI0808421B1 publication Critical patent/BRPI0808421B1/pt

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001122—Ephrin Receptors [Eph]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/422—Ephrin Receptors [Eph]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4225—Growth factors
- A61K40/4229—Transforming growth factor [TGF]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4244—Enzymes
- A61K40/4251—Kinases, e.g. Raf or Src
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4254—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
- C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5047—Cells of the immune system
- G01N33/505—Cells of the immune system involving T-cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/998—Proteins not provided for elsewhere
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Immunology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Biomedical Technology (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Genetics & Genomics (AREA)
Medicinal Chemistry (AREA)
Zoology (AREA)
Biotechnology (AREA)
Wood Science & Technology (AREA)
Microbiology (AREA)
Pharmacology & Pharmacy (AREA)
Cell Biology (AREA)
Biochemistry (AREA)
Hematology (AREA)
General Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Mycology (AREA)
Oncology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Biophysics (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Urology & Nephrology (AREA)
Dispersion Chemistry (AREA)
Tropical Medicine & Parasitology (AREA)
Physics & Mathematics (AREA)
Analytical Chemistry (AREA)
General Physics & Mathematics (AREA)

BRPI0808421-1A 2007-02-21 2008-02-21 Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula BRPI0808421B1 (pt)

Priority Applications (1)

Application Number	Priority Date	Filing Date	Title
BR122020021065-6A BR122020021065B1 (pt)	2007-02-21	2008-02-21	Composição farmacêutica e vacina à base de peptídeos para antígenos associados a tumores expressando câncer, exossomo, método in vitro para induzir células apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica e uso de um peptídeo

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US90294907P	2007-02-21	2007-02-21
US60/902,949		2007-02-21
PCT/JP2008/000290 WO2008102557A1 (en)	2007-02-21	2008-02-21	Peptide vaccines for cancers expressing tumor-associated antigens

Publications (2)

Publication Number	Publication Date
BRPI0808421A2 true BRPI0808421A2 (pt)	2017-08-29
BRPI0808421B1 BRPI0808421B1 (pt)	2021-10-05

Family

ID=39709837

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI0808421-1A BRPI0808421B1 (pt)	2007-02-21	2008-02-21	Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula

Country Status (27)

Country	Link
EP (20)	EP2583976A3 (pt)
JP (6)	JP5239103B2 (pt)
KR (8)	KR20150116463A (pt)
CN (4)	CN104292299B (pt)
AR (1)	AR068302A1 (pt)
AU (1)	AU2008218463B2 (pt)
BR (1)	BRPI0808421B1 (pt)
CA (3)	CA2678755C (pt)
CO (1)	CO6190536A2 (pt)
CY (2)	CY1114590T1 (pt)
DK (3)	DK2476694T3 (pt)
ES (6)	ES2532708T3 (pt)
HR (3)	HRP20131044T1 (pt)
IL (10)	IL200478A (pt)
MX (4)	MX2009009022A (pt)
MY (2)	MY173379A (pt)
NZ (4)	NZ602122A (pt)
PH (1)	PH12014501642A1 (pt)
PL (3)	PL2465864T3 (pt)
PT (2)	PT2121731E (pt)
RU (1)	RU2464275C2 (pt)
SG (3)	SG10201909675QA (pt)
SI (3)	SI2465864T1 (pt)
TW (5)	TWI615403B (pt)
UA (1)	UA100372C2 (pt)
WO (1)	WO2008102557A1 (pt)
ZA (1)	ZA200905881B (pt)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CN1882698B (zh)	2003-08-20	2011-05-25	肿瘤疗法科学股份有限公司	低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
MX2010002018A (es) *	2007-08-20	2010-05-27	Oncotherapy Science Inc	Peptido de cdh3 y agente medicinal que comprende al mismo.
JP5593560B2 (ja)	2008-06-30	2014-09-24	オンコセラピー・サイエンス株式会社	放射性同位体標識で標識された抗ｃｄｈ３抗体およびその使用
TWI580431B (zh) *	2008-08-19	2017-05-01	腫瘤療法科學股份有限公司	Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
TW201008574A (en)	2008-08-19	2010-03-01	Oncotherapy Science Inc	INHBB epitope peptides and vaccines containing the same
US8883966B2 (en) *	2008-10-22	2014-11-11	Oncotherapy Science, Inc.	RAB6KIFL/KIF20A epitope peptide and vaccines containing the same
TWI500932B (zh)	2008-12-05	2015-09-21	Oncotherapy Science Inc	Ｗｄｒｐｕｈ抗原決定位胜肽以及含此胜肽之疫苗
US8735361B2 (en) *	2008-12-24	2014-05-27	Oncotherapy Science, Inc.	C1ORF59 peptides and vaccines including the same
TW201102081A (en)	2009-05-11	2011-01-16	Oncotherapy Science Inc	TTK peptides and vaccines including the same
US8703808B2 (en)	2009-06-23	2014-04-22	Centre National De La Recherche Scientifique	Use of derivatives of indoles for the treatment of cancer
JP5728718B2 (ja)	2009-12-28	2015-06-03	オンコセラピー・サイエンス株式会社	抗ｃｄｈ３抗体およびその使用
DK2547359T3 (en)	2010-03-15	2016-06-06	The Board Of Trustees Of The Univ Of Illionis	Inhibitors of beta integrin G-protein alpha subunit-BINDING INTERACTIONS
TW201627003A (zh) *	2010-04-02	2016-08-01	腫瘤療法科學股份有限公司	Ｅｃｔ２胜肽及含此胜肽之疫苗
UA110119C2 (xx) *	2010-12-02	2015-11-25		Пептиди tomm34 та вакцини, що їх містять
KR102355121B1 (ko)	2011-12-14	2022-02-09	더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템	암 요법을 위한 병립 유전자 비활성화 생물표식과 표적들
US20150359864A1 (en)	2012-03-09	2015-12-17	Oncotherapy Science, Inc.	Pharmaceutical composition containing peptides
EP2872530A4 (en) *	2012-07-10	2016-04-06	Oncotherapy Science Inc	KIF20A EPITOPE PEPTIDES FOR TH1 CELLS AND VACCINES CONTAINING SAME
US9644010B2 (en) *	2012-07-10	2017-05-09	Oncotherapy Science, Inc.	LY6K epitope peptides for TH1 cells and vaccines containing the same
JP5920742B2 (ja)	2012-08-31	2016-05-18	ジーン・ステム株式会社	Ｐｓｆ１由来ペプチド
KR102110873B1 (ko)	2012-09-11	2020-05-14	온코세라피 사이언스 가부시키가이샤	Ube2t 펩티드 및 이를 포함하는 백신
WO2014141652A1 (en) *	2013-03-11	2014-09-18	Oncotherapy Science, Inc.	Smyd3 peptides and vaccines containing the same
TWI658049B (zh)	2013-03-12	2019-05-01	腫瘤療法科學股份有限公司	Ｋｎｔｃ２胜肽及含此胜肽之疫苗
EP3020806A4 (en) *	2013-07-12	2017-05-31	Sumitomo Dainippon Pharma Co., Ltd.	Tumor antigen peptide
JP2015227292A (ja) *	2014-05-30	2015-12-17	国立大学法人高知大学	膵がん細胞浸潤転移抑制ワクチン
EP3164417A1 (en)	2014-07-01	2017-05-10	Pfizer Inc.	Bispecific heterodimeric diabodies and uses thereof
EP3848383A3 (en) *	2014-08-04	2021-11-03	Oncotherapy Science, Inc.	Urlc10-derived peptide and vaccine containing same
GB201507719D0 (en) *	2015-05-06	2015-06-17	Immatics Biotechnologies Gmbh	Novel peptides and combination of peptides and scaffolds thereof for use in immunotherapy against colorectal carcinoma (CRC) and other cancers
CN104975082B (zh) *	2015-06-05	2018-11-02	复旦大学附属肿瘤医院	一组用于评估肺癌预后的基因及其应用
EP3436048B1 (en) *	2016-03-31	2025-06-18	BioNTech US Inc.	Neoantigens and methods of their use
CN110214144B (zh) *	2016-11-16	2023-05-02	深圳华大生命科学研究院	多肽及其应用
ES2913268T3 (es)	2017-01-25	2022-06-01	Ose Immunotherapeutics	Método para fabricar una emulsión estable para la administración de péptidos
CA3058434A1 (en) *	2017-03-28	2018-10-04	Zhenglun Zhu	Methods of treating neoplastic diseases
CN110997903B (zh) *	2017-08-10	2024-03-29	古德T细胞有限公司	用于癌症治疗的t细胞的活化方法
MY182816A (en) *	2018-02-15	2021-02-05	National Univ Corporation Asahikawa Medical Univ	Cancer antigen peptide
KR102322832B1 (ko) *	2019-04-22	2021-11-12	한국과학기술연구원	인간 백혈구 항원 a24:02 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
KR102335916B1 (ko) *	2019-04-22	2021-12-08	한국과학기술연구원	인간 백혈구 항원 a02:01 대립유전자에 특이적으로 결합하는 펩타이드 및 이의 용도
CN113117055A (zh) *	2019-12-31	2021-07-16	上海细胞治疗集团有限公司	一种特异性结合hla-a24分型的多肽组合物及应用
CN117143206B (zh) *	2023-08-03	2024-09-03	华南农业大学	Alv-j mhc-b21限制性表位肽及其筛选方法和应用

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4722848A (en)	1982-12-08	1988-02-02	Health Research, Incorporated	Method for immunizing animals with synthetically modified vaccinia virus
NZ231899A (en) *	1985-10-03	1991-07-26	Genentech Inc	Human or porcine inhibin peptide compositions and dna encoding them
US5703055A (en)	1989-03-21	1997-12-30	Wisconsin Alumni Research Foundation	Generation of antibodies through lipid mediated DNA delivery
CA2084180A1 (en) *	1991-12-11	1993-06-12	Paul P. Hung	Expression of specific immunogens using viral antigens
US5679647A (en)	1993-08-26	1997-10-21	The Regents Of The University Of California	Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
US5804566A (en)	1993-08-26	1998-09-08	The Regents Of The University Of California	Methods and devices for immunizing a host through administration of naked polynucleotides with encode allergenic peptides
US5739118A (en)	1994-04-01	1998-04-14	Apollon, Inc.	Compositions and methods for delivery of genetic material
WO1995028484A1 (en) *	1994-04-15	1995-10-26	Amgen Inc.	Hek5, hek7, hek8, hek11, new eph-like receptor protein tyrosine kinases
US5736524A (en)	1994-11-14	1998-04-07	Merck & Co.,. Inc.	Polynucleotide tuberculosis vaccine
US5922687A (en)	1995-05-04	1999-07-13	Board Of Trustees Of The Leland Stanford Junior University	Intracellular delivery of nucleic acids using pressure
CA2225553A1 (en)	1995-08-03	1997-02-20	Rijksuniversiteit Te Leiden	Cell derived antigen presenting vesicles
US5853719A (en)	1996-04-30	1998-12-29	Duke University	Methods for treating cancers and pathogen infections using antigen-presenting cells loaded with RNA
US6294378B1 (en)	1996-07-26	2001-09-25	Sloan-Kettering Institute For Cancer Research	Method and reagents for genetic immunization
AU6795898A (en) *	1997-04-04	1998-10-30	Board Of Regents, The University Of Texas System	Proteins and compositions for modulating mitosis
FR2766205B1 (fr)	1997-07-16	2002-08-30	Inst Nat Sante Rech Med	Nouveau procede de sensibilisation de cellules presentatrices d'antigene et nouveaux moyens pour la mise en oeuvre du procede
WO1999018126A1 (fr) *	1997-10-07	1999-04-15	Ono Pharmaceutical Co., Ltd.	POLYPEPTIDE, ADNc LE CODANT ET LEUR UTILISATION
US20070014787A1 (en) *	1998-07-15	2007-01-18	Human Genome Sciences, Inc.	71 human secreted proteins
AU1220001A (en) *	1999-10-20	2001-04-30	Zymogenetics Inc.	Novel proteins and polynucleotides encoding them
US6682902B2 (en) *	1999-12-16	2004-01-27	Schering Aktiengesellschaft	DNA encoding a novel RG1 polypeptide
US20030013649A1 (en) *	2000-01-31	2003-01-16	Rosen Craig A.	Nucleic acids, proteins, and antibodies
CN1469926A (zh) *	2000-03-29	2004-01-21	科里克萨有限公司	治疗和诊断肺癌的组合物和方法
US7118853B2 (en)	2000-07-26	2006-10-10	Applied Genomics, Inc.	Methods of classifying, diagnosing, stratifying and treating cancer patients and their tumors
US6830885B1 (en) *	2000-08-18	2004-12-14	Phenogene Therapeutiques Inc.	Nucleic acid molecule, method and kit for selecting a nucleic acid having a desired feature
US20090062512A1 (en) *	2000-10-10	2009-03-05	Hildebrand William H	Comparative ligand mapping from MHC class I positive cells
US7919467B2 (en) *	2000-12-04	2011-04-05	Immunotope, Inc.	Cytotoxic T-lymphocyte-inducing immunogens for prevention, treatment, and diagnosis of cancer
CN100400099C (zh) *	2001-01-04	2008-07-09	北京迪威华宇生物技术有限公司	预防和治疗人前列腺癌的重组蛋白疫苗
AU2002311787A1 (en) *	2001-03-28	2002-10-15	Zycos Inc.	Translational profiling
EP1463928A2 (en) *	2001-04-18	2004-10-06	Protein Design Labs	Methods of diagnosis of lung cancer, compositions and methods of screening for modulators of lung cancer
JP2005508144A (ja) *	2001-06-18	2005-03-31	イオスバイオテクノロジー，インコーポレイティド	卵巣癌の診断方法、卵巣癌のモジュレーターをスクリーニングする組成物及び方法
US20030124579A1 (en) *	2001-09-05	2003-07-03	Eos Biotechnology, Inc.	Methods of diagnosis of ovarian cancer, compositions and methods of screening for modulators of ovarian cancer
US20060088532A1 (en) *	2002-03-07	2006-04-27	Kari Alitalo	Lymphatic and blood endothelial cell genes
US20030194704A1 (en) *	2002-04-03	2003-10-16	Penn Sharron Gaynor	Human genome-derived single exon nucleic acid probes useful for gene expression analysis two
US20070015271A1 (en) *	2002-04-04	2007-01-18	Rosen Craig A	Human secreted proteins
EP1594447A2 (en) *	2002-10-02	2005-11-16	Genentech, Inc.	Compositions and methods for the diagnosis and treatment of tumor
EP1572736A2 (en) *	2002-12-10	2005-09-14	Endocube SAS	Thap proteins as nuclear receptors for chemokines and roles in transcriptional regulation, cell proliferation and cell differentiation
WO2004058153A2 (en) *	2002-12-20	2004-07-15	Millennium Pharmaceuticals, Inc.	Methods and compositions for treating cancer using 15986, 2188, 20743, 9148, 9151, 9791, 44252, 14184, 42461, 8204, 7970, 25552, 21657, 26492, 2411, 15088, 1905, 28899, 63380, 33935, 10480, 12686, 25501, 17694, 15701, 53062, 49908, 21612, 38949, 6216, 46863, 9235, 2201, 6985, 9883, 12238, 18057, 21617, 39228, 49928, 54476.
TWI324608B (en) *	2003-02-28	2010-05-11	Oncotherapy Science Inc	Genes and polypeptides relating to human colorectal cancers
EP1651775A2 (en) *	2003-06-18	2006-05-03	Arcturus Bioscience, Inc.	Breast cancer survival and recurrence
WO2005019258A2 (en) *	2003-08-11	2005-03-03	Genentech, Inc.	Compositions and methods for the treatment of immune related diseases
CN1882698B (zh) *	2003-08-20	2011-05-25	肿瘤疗法科学股份有限公司	低氧可诱导的蛋白2(hig2)作为新的治疗肾细胞癌(rcc)的潜在标靶
US20070253954A1 (en) *	2004-02-27	2007-11-01	Oncotherapy Science, Inc.	Epha4 As Therapeutic Target Of Prc And Pdaca
US8193332B2 (en) *	2004-04-09	2012-06-05	Genecare Research Institute Co., Ltd.	Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes
JP2008509654A (ja) *	2004-06-01	2008-04-03	イノジェネティックス・ナムローゼ・フェンノートシャップ	Ｃ型肝炎ウイルスに対するｃｔｌおよび／またはｈｔｌ応答を誘導するためのペプチド
CA2580412A1 (en)	2004-09-13	2006-03-23	Government Of The United States Of America, Represented By The Secretary , Department Of Health And Human Services	Compositions comprising t cell receptors and methods of use thereof
CN100381460C (zh) *	2004-11-30	2008-04-16	北京市肿瘤防治研究所	Her-2模拟抗原表位及含有该表位的肽
RU2007135030A (ru) *	2005-02-24	2009-03-27	Симайнз, Инк. (Us)	Композиции и способы классификации биологических образцов
US7847060B2 (en) *	2005-02-25	2010-12-07	Oncotherapy Science, Inc.	Peptide vaccines for lung cancers expressing TTK, URLC10 or KOC1 polypeptides
CN100348614C (zh) *	2005-06-03	2007-11-14	北京大学	一种肝癌－睾丸特异性抗原蛋白质和抗原肽
US8030443B2 (en) *	2005-08-09	2011-10-04	Kurume University	Squamous cell carcinoma antigen-derived peptide binding to HLA-A24 molecule
WO2007018199A1 (ja) *	2005-08-09	2007-02-15	Kumamoto University	HLA-A2陽性者用glypican-3(GPC3)由来癌拒絶抗原ペプチド及びこれを含む医薬
US8003770B2 (en)	2005-09-13	2011-08-23	Mie University	T-cell receptor and nucleic acid encoding the receptor
WO2007064743A2 (en) *	2005-11-30	2007-06-07	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in leukemia signaling pathways
ES2385261T3 (es) *	2006-04-10	2012-07-20	Genentech, Inc.	Moduladores de PDZ Disheveled
AU2007259667B2 (en) *	2006-06-16	2012-06-14	Oncotherapy Science, Inc.	SPARC-derived tumor rejection antigenic peptides and medicaments comprising the same
EP1972639A3 (en) *	2007-03-07	2008-12-03	Cell Signaling Technology, Inc.	Reagents for the detection of protein phosphorylation in carcinoma signaling pathways
EP1983003A3 (en) *	2007-04-19	2009-03-11	Peter Hornbeck	Tyrosine phosphorylation sites and antibodies specific for them
MX2010002018A (es) *	2007-08-20	2010-05-27	Oncotherapy Science Inc	Peptido de cdh3 y agente medicinal que comprende al mismo.
EP2080812A1 (en) *	2008-01-18	2009-07-22	Transmedi SA	Compositions and methods of detecting post-stop peptides
TWI580431B (zh) *	2008-08-19	2017-05-01	腫瘤療法科學股份有限公司	Ｈｉｇ２與ｕｒｌｃ１０抗原決定位胜肽以及含此胜肽之疫苗
WO2011039289A1 (de) *	2009-09-29	2011-04-07	Protagen Ag	Markersequenzen für pankreaskrebserkrankungen, pankreaskarzinom und deren verwendung

2008
- 2008-02-18 TW TW105108412A patent/TWI615403B/zh not_active IP Right Cessation
- 2008-02-18 TW TW097105594A patent/TWI438207B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103114624A patent/TWI494319B/zh not_active IP Right Cessation
- 2008-02-18 TW TW104120673A patent/TWI596109B/zh not_active IP Right Cessation
- 2008-02-18 TW TW103107156A patent/TWI610939B/zh active
- 2008-02-21 HR HRP20131044AT patent/HRP20131044T1/hr unknown
- 2008-02-21 SG SG10201909675Q patent/SG10201909675QA/en unknown
- 2008-02-21 KR KR1020157026286A patent/KR20150116463A/ko not_active Abandoned
- 2008-02-21 EP EP12175488.1A patent/EP2583976A3/en not_active Withdrawn
- 2008-02-21 EP EP12151719.7A patent/EP2465865B1/en not_active Not-in-force
- 2008-02-21 CA CA2678755A patent/CA2678755C/en active Active
- 2008-02-21 NZ NZ602122A patent/NZ602122A/en not_active IP Right Cessation
- 2008-02-21 SI SI200831332T patent/SI2465864T1/sl unknown
- 2008-02-21 DK DK12151717.1T patent/DK2476694T3/en active
- 2008-02-21 EP EP12151717.1A patent/EP2476694B1/en active Active
- 2008-02-21 PT PT87104436T patent/PT2121731E/pt unknown
- 2008-02-21 EP EP12175480.8A patent/EP2567971A3/en not_active Withdrawn
- 2008-02-21 NZ NZ591704A patent/NZ591704A/xx not_active IP Right Cessation
- 2008-02-21 EP EP12175482.4A patent/EP2570429A3/en not_active Withdrawn
- 2008-02-21 ES ES12151714.8T patent/ES2532708T3/es active Active
- 2008-02-21 MX MX2009009022A patent/MX2009009022A/es active IP Right Grant
- 2008-02-21 CA CA2992074A patent/CA2992074C/en active Active
- 2008-02-21 UA UAA200909469A patent/UA100372C2/ru unknown
- 2008-02-21 JP JP2009534784A patent/JP5239103B2/ja active Active
- 2008-02-21 NZ NZ602119A patent/NZ602119A/en not_active IP Right Cessation
- 2008-02-21 CN CN201410449753.0A patent/CN104292299B/zh active Active
- 2008-02-21 AU AU2008218463A patent/AU2008218463B2/en not_active Ceased
- 2008-02-21 ES ES12151705.6T patent/ES2541863T3/es active Active
- 2008-02-21 PT PT121517114T patent/PT2465864E/pt unknown
- 2008-02-21 KR KR1020157013656A patent/KR101644871B1/ko not_active Expired - Fee Related
- 2008-02-21 NZ NZ579768A patent/NZ579768A/en not_active IP Right Cessation
- 2008-02-21 PL PL12151711T patent/PL2465864T3/pl unknown
- 2008-02-21 KR KR1020147026728A patent/KR101543623B1/ko not_active Expired - Fee Related
- 2008-02-21 DK DK08710443.6T patent/DK2121731T3/da active
- 2008-02-21 KR KR1020167010159A patent/KR20160045939A/ko not_active Withdrawn
- 2008-02-21 SI SI200831368T patent/SI2476694T1/sl unknown
- 2008-02-21 EP EP12175489.9A patent/EP2594582A3/en not_active Withdrawn
- 2008-02-21 KR KR1020137004417A patent/KR101511140B1/ko active Active
- 2008-02-21 ES ES12151711.4T patent/ES2527397T3/es active Active
- 2008-02-21 EP EP12151722.1A patent/EP2465867B1/en active Active
- 2008-02-21 ES ES12151717T patent/ES2530777T3/es active Active
- 2008-02-21 MX MX2016002567A patent/MX359680B/es unknown
- 2008-02-21 ES ES12151722.1T patent/ES2540893T3/es active Active
- 2008-02-21 RU RU2009135020/10A patent/RU2464275C2/ru active
- 2008-02-21 SG SG10201506589WA patent/SG10201506589WA/en unknown
- 2008-02-21 ES ES08710443T patent/ES2435194T3/es active Active
- 2008-02-21 CN CN200880012937.3A patent/CN101663315B/zh active Active
- 2008-02-21 AR ARP080100718A patent/AR068302A1/es unknown
- 2008-02-21 KR KR1020157002221A patent/KR101644877B1/ko not_active Expired - Fee Related
- 2008-02-21 MX MX2013009906A patent/MX337417B/es unknown
- 2008-02-21 PL PL08710443T patent/PL2121731T3/pl unknown
- 2008-02-21 MY MYPI2012004306A patent/MY173379A/en unknown
- 2008-02-21 EP EP12175487.3A patent/EP2573110A3/en not_active Withdrawn
- 2008-02-21 EP EP12175483.2A patent/EP2570430A3/en not_active Withdrawn
- 2008-02-21 WO PCT/JP2008/000290 patent/WO2008102557A1/en active Application Filing
- 2008-02-21 EP EP12151714.8A patent/EP2476693B1/en active Active
- 2008-02-21 MX MX2013009905A patent/MX337456B/es unknown
- 2008-02-21 EP EP12151720A patent/EP2465866A3/en not_active Withdrawn
- 2008-02-21 EP EP08710443.6A patent/EP2121731B1/en active Active
- 2008-02-21 SG SG2012012126A patent/SG179402A1/en unknown
- 2008-02-21 KR KR1020097019583A patent/KR101511134B1/ko not_active Expired - Fee Related
- 2008-02-21 DK DK12151711.4T patent/DK2465864T3/en active
- 2008-02-21 EP EP12175478A patent/EP2565203A1/en not_active Withdrawn
- 2008-02-21 EP EP12175479.0A patent/EP2573109A3/en not_active Withdrawn
- 2008-02-21 EP EP12151705.6A patent/EP2476692B1/en not_active Not-in-force
- 2008-02-21 CA CA2919248A patent/CA2919248A1/en not_active Abandoned
- 2008-02-21 EP EP12175490.7A patent/EP2574623A3/en not_active Withdrawn
- 2008-02-21 KR KR1020147026715A patent/KR101540000B1/ko not_active Expired - Fee Related
- 2008-02-21 CN CN201210352621.7A patent/CN102863514B/zh active Active
- 2008-02-21 EP EP12151723A patent/EP2476695A3/en not_active Withdrawn
- 2008-02-21 EP EP12175484.0A patent/EP2594581A3/en not_active Withdrawn
- 2008-02-21 BR BRPI0808421-1A patent/BRPI0808421B1/pt not_active IP Right Cessation
- 2008-02-21 EP EP12175481.6A patent/EP2570428A3/en not_active Withdrawn
- 2008-02-21 PL PL12151717T patent/PL2476694T3/pl unknown
- 2008-02-21 SI SI200831053T patent/SI2121731T1/sl unknown
- 2008-02-21 EP EP12151711.4A patent/EP2465864B1/en not_active Not-in-force
- 2008-02-21 MY MYPI20093446A patent/MY155029A/en unknown
- 2008-02-21 CN CN201310183458.0A patent/CN103351423B/zh active Active
2009
- 2009-08-18 IL IL200478A patent/IL200478A/en active IP Right Grant
- 2009-08-25 ZA ZA200905881A patent/ZA200905881B/xx unknown
- 2009-09-21 CO CO09102283A patent/CO6190536A2/es not_active Application Discontinuation
2010
- 2010-02-02 JP JP2010021234A patent/JP5239104B2/ja active Active
2012
- 2012-04-04 IL IL219044A patent/IL219044A/en active IP Right Grant
- 2012-04-04 IL IL219040A patent/IL219040A/en active IP Right Grant
- 2012-04-04 IL IL219041A patent/IL219041A/en not_active IP Right Cessation
- 2012-04-04 IL IL219043A patent/IL219043A/en not_active IP Right Cessation
- 2012-04-04 IL IL219045A patent/IL219045A0/en unknown
- 2012-04-04 IL IL219042A patent/IL219042A/en not_active IP Right Cessation
- 2012-04-04 IL IL219046A patent/IL219046A/en not_active IP Right Cessation
- 2012-04-04 IL IL219048A patent/IL219048A/en not_active IP Right Cessation
- 2012-04-04 IL IL219047A patent/IL219047A0/en unknown
- 2012-11-29 JP JP2012260412A patent/JP5614761B2/ja active Active
- 2012-11-29 JP JP2012260421A patent/JP5608953B2/ja active Active
2013
- 2013-11-08 CY CY20131100994T patent/CY1114590T1/el unknown
2014
- 2014-07-17 PH PH12014501642A patent/PH12014501642A1/en unknown
- 2014-07-24 JP JP2014150295A patent/JP5874158B2/ja not_active Expired - Fee Related
- 2014-12-17 HR HRP20141233AT patent/HRP20141233T1/hr unknown
- 2014-12-18 CY CY20141101067T patent/CY1115841T1/el unknown
2015
- 2015-01-28 HR HRP20150108TT patent/HRP20150108T1/hr unknown
- 2015-12-25 JP JP2015252737A patent/JP2016094459A/ja active Pending

Also Published As

Publication number	Publication date
JP2014210804A (ja)	2014-11-13
JP2010519176A (ja)	2010-06-03
CA2678755A1 (en)	2008-08-28
CN102863514A (zh)	2013-01-09
PL2476694T3 (pl)	2015-04-30
AU2008218463A2 (en)	2009-11-26
HK1172344A1 (en)	2013-04-19
HK1172346A1 (en)	2013-04-19
EP2476692B1 (en)	2015-04-15
KR20140130507A (ko)	2014-11-10
EP2476692A2 (en)	2012-07-18
NZ579768A (en)	2012-03-30
EP2570430A2 (en)	2013-03-20
EP2476693B1 (en)	2014-12-24
EP2121731B1 (en)	2013-08-14
EP2594582A2 (en)	2013-05-22
EP2567971A2 (en)	2013-03-13
CY1115841T1 (el)	2017-01-25
CN104292299A (zh)	2015-01-21
HRP20131044T1 (hr)	2013-12-06
IL219047A0 (en)	2012-05-31
ES2435194T3 (es)	2013-12-16
EP2476693A3 (en)	2012-10-03
TW200844111A (en)	2008-11-16
IL219042A (en)	2016-03-31
IL219040A0 (en)	2012-05-31
IL219044A (en)	2014-12-31
EP2567971A3 (en)	2013-06-26
EP2465864A2 (en)	2012-06-20
HK1134507A1 (en)	2010-04-30
ES2541863T3 (es)	2015-07-27
EP2465867A3 (en)	2012-10-10
EP2476695A3 (en)	2012-12-12
EP2570428A3 (en)	2013-07-10
KR101644871B1 (ko)	2016-08-02
MY155029A (en)	2015-08-28
TWI494319B (zh)	2015-08-01
JP5874158B2 (ja)	2016-03-02
MX359680B (es)	2018-09-28
EP2465865B1 (en)	2016-11-02
BRPI0808421B1 (pt)	2021-10-05
SI2476694T1 (sl)	2015-02-27
TWI438207B (zh)	2014-05-21
MX337417B (es)	2016-03-03
KR20150064236A (ko)	2015-06-10
JP5239104B2 (ja)	2013-07-17
PT2465864E (pt)	2015-01-14
KR20090121349A (ko)	2009-11-25
EP2465865A3 (en)	2013-07-24
PL2121731T3 (pl)	2014-01-31
HK1172041A1 (en)	2013-04-12
EP2476695A2 (en)	2012-07-18
KR101511140B1 (ko)	2015-04-10
AU2008218463A1 (en)	2008-08-28
IL219040A (en)	2014-12-31
IL219046A (en)	2015-02-26
KR101540000B1 (ko)	2015-07-29
IL219044A0 (en)	2012-05-31
NZ602119A (en)	2014-03-28
EP2574623A3 (en)	2013-07-17
ZA200905881B (en)	2010-05-26
AU2008218463B2 (en)	2013-01-17
IL219048A (en)	2015-07-30
EP2476694B1 (en)	2014-11-19
CA2919248A1 (en)	2008-08-28
EP2583976A2 (en)	2013-04-24
JP5608953B2 (ja)	2014-10-22
CN102863514B (zh)	2014-12-10
KR20150116463A (ko)	2015-10-15
EP2465866A2 (en)	2012-06-20
SG10201506589WA (en)	2015-09-29
CN103351423B (zh)	2016-09-28
EP2570429A3 (en)	2013-08-28
DK2465864T3 (en)	2014-11-24
IL200478A (en)	2015-11-30
JP2010209060A (ja)	2010-09-24
SG10201909675QA (en)	2019-11-28
CY1114590T1 (el)	2016-10-05
KR101511134B1 (ko)	2015-04-28
TW201433574A (zh)	2014-09-01
EP2570428A2 (en)	2013-03-20
EP2573109A3 (en)	2013-06-19
TWI615403B (zh)	2018-02-21
HK1172042A1 (en)	2013-04-12
NZ591704A (en)	2012-09-28
NZ602122A (en)	2014-03-28
RU2009135020A (ru)	2011-03-27
EP2573110A3 (en)	2013-09-04
PL2465864T3 (pl)	2015-03-31
TW201422637A (zh)	2014-06-16
EP2476693A2 (en)	2012-07-18
EP2574623A2 (en)	2013-04-03
IL200478A0 (en)	2010-04-29
WO2008102557A1 (en)	2008-08-28
IL219043A0 (en)	2012-05-31
IL219046A0 (en)	2012-05-31
EP2465866A3 (en)	2012-10-10
KR101644877B1 (ko)	2016-08-03
ES2532708T3 (es)	2015-03-31
JP2016094459A (ja)	2016-05-26
TWI610939B (zh)	2018-01-11
JP5239103B2 (ja)	2013-07-17
SI2465864T1 (sl)	2014-12-31
CN104292299B (zh)	2017-09-29
IL219045A0 (en)	2012-05-31
IL219043A (en)	2014-12-31
HRP20150108T1 (hr)	2015-05-08
EP2476694A3 (en)	2013-04-24
KR20150018895A (ko)	2015-02-24
TW201538522A (zh)	2015-10-16
HRP20141233T1 (hr)	2015-02-27
CN101663315A (zh)	2010-03-03
JP5614761B2 (ja)	2014-10-29
EP2465867A2 (en)	2012-06-20
ES2530777T3 (es)	2015-03-05
UA100372C2 (ru)	2012-12-25
CN103351423A (zh)	2013-10-16
EP2476694A2 (en)	2012-07-18
EP2121731A1 (en)	2009-11-25
PH12014501642B1 (en)	2015-12-02
AR068302A1 (es)	2009-11-11
JP2013116895A (ja)	2013-06-13
KR20140121489A (ko)	2014-10-15
JP2013091645A (ja)	2013-05-16
CO6190536A2 (es)	2010-08-19
PT2121731E (pt)	2013-10-24
KR20160045939A (ko)	2016-04-27
EP2573109A2 (en)	2013-03-27
CA2678755C (en)	2016-04-26
DK2121731T3 (da)	2013-10-21
HK1172043A1 (en)	2013-04-12
RU2464275C2 (ru)	2012-10-20
KR101543623B1 (ko)	2015-08-11
IL219042A0 (en)	2012-05-31
EP2465864A3 (en)	2012-10-03
SG179402A1 (en)	2012-04-27
CA2992074A1 (en)	2008-08-28
TW201623325A (zh)	2016-07-01
KR20130023407A (ko)	2013-03-07
IL219041A0 (en)	2012-05-31
EP2583976A3 (en)	2013-10-23
SI2121731T1 (sl)	2013-10-30
TWI596109B (zh)	2017-08-21
EP2594581A3 (en)	2013-08-14
EP2594582A3 (en)	2013-08-14
EP2121731A4 (en)	2010-04-21
EP2570429A2 (en)	2013-03-20
IL219041A (en)	2014-12-31
EP2465867B1 (en)	2015-04-01
EP2465864B1 (en)	2014-10-08
EP2565203A1 (en)	2013-03-06
MY173379A (en)	2020-01-21
PH12014501642A1 (en)	2015-12-02
EP2476692A3 (en)	2012-12-19
EP2465865A2 (en)	2012-06-20
IL219048A0 (en)	2012-05-31
EP2594581A2 (en)	2013-05-22
ES2527397T3 (es)	2015-01-23
HK1172345A1 (en)	2013-04-19
MX2009009022A (es)	2010-03-03
MX337456B (es)	2016-03-03
EP2570430A3 (en)	2013-07-10
CA2992074C (en)	2021-01-05
CN101663315B (zh)	2014-10-15
ES2540893T3 (es)	2015-07-14
DK2476694T3 (en)	2014-12-08
EP2573110A2 (en)	2013-03-27

Publication	Publication Date	Title
BRPI0808421A2 (pt)	2017-08-29	Composição farmacêutica para tratar câncer, exossomo, uso de um peptídeo, métodos in vitro para induzir uma célula apresentando antígeno que têm uma alta inducibilidade de célula t citotóxica ou para induzir células t citotóxicas e vacina para inibir a proliferação de uma célula.
CL2008001633A1 (es)	2008-12-12	Compuestos derivados de pirrolidin-3-carboxamida; composición farmacéutica; y uso comominhibidores de erk para el tratamiento del cancer.
CL2011001536A1 (es)	2011-10-14	Compuestos derivados de pirimidin-2-il-1h-indol, inhibidores de la proteina quinasa atr; composicion farmaceutica que comprende a uno de los compuestos; y uso de los compuestos en la preparacion de medicamentos utiles para el tratamiento del cancer.
MX2009008926A (es)	2009-09-14	Aplicaciones terapeuticas de activacion de celulas que presentan antigeno humano por medio de detectina a-1.
CL2007003520A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso para el tratamiento profilactico o terapeutico del cancer.
CL2009000483A1 (es)	2010-02-19	Compuestos derivados de n-(piridin-3-il)-1,3-tiazol-5-amino-4-carboxamida, inhibidores de cinasa pim; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2007003523A1 (es)	2008-08-22	Compuestos derivados de heterociclos sustituidos con morfolina, inhibidores de la actividad de pi3 quinasa; composicion farmaceutica que comprende a dichos compuestos; kit farmaceutico; y su uso en el tratamiento profilactico o terapeutico del cancer
CL2011001232A1 (es)	2012-02-10	Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
CL2012003026A1 (es)	2013-02-01	Composicion farmaceutica que comprende pioglitazona y linagliptina; procedimiento de preparacion; uso en el tratamiento de la diabetes tipo 2 o la obesidad.
BR112015014969A2 (pt)	2017-07-11	micromatriz para entrega de agente terapêutico e métodos de uso
CL2012002189A1 (es)	2012-11-23	Compuestos derivados de pirrolidina-2-carboxamidas sustituidas; inhibidores de la interaccion mdm2-p53; composicion farmaceutica; y su uso para el tratamiento del cancer, en particular de tumores solidos.
CL2012002606A1 (es)	2013-10-18	Composicion farmaceutica que comprende (-)-carvona, (+)-carvona, trans-geraniol y al menos un componente elegido de aceites esenciales para uso en el tratamiento y prevencion de enfermedades virales.
CL2007002635A1 (es)	2009-10-23	Compuestos derivados de quinazolinona e isoquinolinona, moduladores de la actividad del eje hpa; composicion farmaceutica que los comprende; y su uso en el tratamiento y/o prevencion relacionado con estres o depresion.
CL2008002243A1 (es)	2009-08-21	Compuestos derivados de 2-pirazolamino-1,3,5-triazina, inhibidores de kinasa jak; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento del cancer.
CL2007000311A1 (es)	2008-01-25	Compuestos derivados de cromen-2-ona; composicion farmaceutica que los comprende;y su uso en el trastamiento de un trastorno proliferativos como es el cancer.
CL2007003138A1 (es)	2008-06-27	Compuestos derivados de anilinopiperazina; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento del cancer.
CL2007002234A1 (es)	2008-06-13	Compuestos derivados de heterociclos de nitrogeno; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto para el tratamiento de enfermedades proliferativas.
CL2011000691A1 (es)	2011-07-29	Compuestos derivados de nicotinamida sustituida; composicion farmaceutica que los comprende; uso para el tratamiento y/o prevencion de cancer, infecciones, enfermedades inflamatorias y autoinmunitarias.
CL2012000772A1 (es)	2012-08-24	Compuestos derivados de hetorociclos carboxamidicos sustituidos, antagonista ar; composición farmacéutica que los comprende; y uso en el tratamiento del cáncer de próstata.
CL2011000301A1 (es)	2011-07-15	Compuestos derivados de purina con actividad inmunomoduladora; composición farmacéutica que los comprende; y uso de ellos en el tratamiento de enfermedades alérgicas, rinitis alérgica, asma, enfermedades infecciosas y cáncer.
BRPI0810524A2 (pt)	2014-10-21	Derivado de (aza)indol e uso do mesmo para propósitos médicos
CL2008002381A1 (es)	2009-02-13	Oligonucleotido inmunoestimulador; composicion farmaceutica que lo comprende; y su uso para tratar un trastorno o afeccion en un sujeto, incluyendo cancer.
CL2007001435A1 (es)	2008-01-25	Compuestos derivados de fenilalanina; proceso de prepatacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto como inhibidores de integrina para el tratamiento del cancer.
BRPI0810208A2 (pt)	2014-10-21	Combinação de terapias compreendendo inibidores p13k-alpha à base de quinoxalina para uso no tratamento do câncer.
CL2008000022A1 (es)	2008-05-16	Compuestos derivados de fenil-(4-fenil pirimidin-2-il)-aminas; composicion farmaceutica que comprende a dichos compuestos ; procedimiento de preparacion de dichos compuestos; y su uso en enfermedades inflamatorias, diabetes y cancer.

Legal Events

Date	Code	Title	Description
2018-04-24	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2019-06-25	B07D	Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
2020-05-19	B07E	Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
2020-08-18	B06U	Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
2021-03-02	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2021-04-20	B06F	Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
2021-08-03	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2021-10-05	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 21/02/2008, OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF, QUE DETERMINA A ALTERACAO DO PRAZO DE CONCESSAO.
2023-12-12	B21F	Lapse acc. art. 78, item iv - on non-payment of the annual fees in time	Free format text: REFERENTE A 16A ANUIDADE.
2024-04-02	B24J	Lapse because of non-payment of annual fees (definitively: art 78 iv lpi, resolution 113/2013 art. 12)	Free format text: EM VIRTUDE DA EXTINCAO PUBLICADA NA RPI 2762 DE 12-12-2023 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDA A EXTINCAO DA PATENTE E SEUS CERTIFICADOS, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.